TKT Replagal Surrogate Data Should Be Reworked For Accelerated Approval
Executive Summary
Transkaryotic Therapeutics' Replagal histologic data should be reevaluated to determine whether they may satisfy a surrogate endpoint for accelerated approval in Fabry Disease, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Jan. 14
You may also be interested in...
Replagal Advisory Committee Will Include Closed Door Session On Manufacturing
FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.
TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA
Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006
TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA
Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006